Evidence mapPaperPMID 39599686Full record

Trial reportNutrients2024

Carnosine Supplementation Has No Effect on Inflammatory Markers in Adults with Prediabetes and Type 2 Diabetes: A Randomised Controlled Trial.

Saeede Saadati, Maximilian de Courten, Cyril Deceneux, Magdalena Plebanski, David Scott, Jakub Mesinovic, Paul Jansons, Giancarlo Aldini, James Cameron, Jack Feehan and 2 more

Registry-linked trialAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Nutrients, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02917928 (The Potential of Carnosine Supplementation in Optimising Cardiometabolic Health in Patients With Prediabetes and Type 2 Diabetes), which is not on this map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02917928 phase2unknown statusnot on this map

The Potential of Carnosine Supplementation in Optimising Cardiometabolic Health in Patients With Prediabetes and Type 2 Diabetes: a Randomsied, Double-blinded, Placebo-controlled Trial

TypeinterventionalSponsorMonash UniversityRan2016 to 2023Enrolled40ConditionsPoor Glycemic Control, Cardiovascular Risk Factors, Cognitive Function 1, SocialArmscarnosine, Placebo
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Histidine-Containing Dipeptides in Obesity and Cardiometabolic Health: A Systematic Scoping Review.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2025
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Saeede SaadatiMonash Centre for Health Research and Implementation (MCHRI), Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, VIC 3168, Australia.ORCID 0000-0002-5352-0670
Maximilian de CourtenAustralian Health Policy Collaboration, Institute for Health and Sport (IHES), Victoria University, Melbourne, VIC 8001, Australia.ORCID 0000-0001-9997-9359
Cyril DeceneuxCancer Aging and Vaccine Laboratory, School of Health and Biomedical Sciences, RMIT University, Bundoora, VIC 3083, Australia.ORCID 0000-0002-8074-045X
Magdalena PlebanskiCancer Aging and Vaccine Laboratory, School of Health and Biomedical Sciences, RMIT University, Bundoora, VIC 3083, Australia.ORCID 0000-0001-6889-3667
David ScottInstitute for Physical Activity and Nutrition (IPAN), School of Exercise and Nutrition Sciences, Deakin University, Geelong, VIC 3220, Australia.ORCID 0000-0001-5226-1972
Jakub MesinovicInstitute for Physical Activity and Nutrition (IPAN), School of Exercise and Nutrition Sciences, Deakin University, Geelong, VIC 3220, Australia.
Paul JansonsInstitute for Physical Activity and Nutrition (IPAN), School of Exercise and Nutrition Sciences, Deakin University, Geelong, VIC 3220, Australia.
Giancarlo AldiniDepartment of Pharmaceutical Sciences, University of Milan, 20133 Milan, Italy.ORCID 0000-0002-2355-6744
James CameronSchool of Clinical Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, VIC 3168, Australia.ORCID 0000-0003-0589-0367
Jack FeehanSchool of Health and Biomedical Sciences, RMIT University, Bundoora, VIC 3083, Australia.
Aya MousaMonash Centre for Health Research and Implementation (MCHRI), Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, VIC 3168, Australia.ORCID 0000-0002-7356-4523
Barbora de CourtenSchool of Clinical Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, VIC 3168, Australia.ORCID 0000-0001-8760-2511

Funding

RACP Prof. Barbora de Courten
6 · The paper itself

Abstract

BACKGROUND/

objectivesIn vitro studies suggest that carnosine reduces inflammation by upregulating anti-inflammatory mediators and downregulating pro-inflammatory cytokines. However, human clinical trials examining the effects of carnosine on inflammatory biomarkers are scant. We conducted a secondary analysis of a double-blind randomised controlled trial (RCT) to examine the effects of carnosine supplementation on inflammatory markers and adipokines in participants with prediabetes or well-controlled type 2 diabetes (T2D).

methodsOut of 88 participants who were recruited, 49 adults with prediabetes or well-controlled T2D (HbA1c: 6.6 ± 0.7% [mean ± SD]) who were treated with diet and/or metformin were eligible for inclusion. Participants were randomised to receive 2 g/day of carnosine or a matching placebo for 14 weeks. We measured serum concentrations of monocyte chemoattractant protein-1 (MCP-1), interleukin (IL)-6, IL-10, C-reactive protein (CRP), tumour necrosis factor-α (TNF-α), adiponectin, leptin, adipsin, serpin, and resistin levels at baseline and after 14 weeks. The trial was registered at clinicaltrials.gov (NCT02917928).

resultsForty-one participants (M = 29/F = 12) aged 53 (42.6, 59.3) years [median (IQR)] completed the trial. After 14 weeks of supplementation, changes in pro- and anti-inflammatory cytokine and adipokine levels did not differ between the carnosine and placebo groups (

conclusionsIn individuals with prediabetes and well-controlled T2D, carnosine supplementation did not result in any significant changes in inflammatory markers. Larger RCTs with longer follow-up durations are needed to evaluate whether carnosine may be beneficial in individuals with poorly controlled T2D.

Indexed as

BiomarkersCarnosineDiabetes Mellitus, Type 2Dietary SupplementsPrediabetic StateAdipokinesAdultAgedC-Reactive ProteinCytokinesDouble-Blind MethodFemaleHumansInflammationInflammation MediatorsMaleAdipokinesBiomarkersCarnosineC-Reactive ProteinCytokinesInflammation Mediatorscarnosinecytokineinflammationinsulin resistanceprediabetesrandomised trialtype 2 diabetes

Identifiers

PMID39599686
PMCPMC11597812

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.